Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Francisco, California 94143


Patients with chronic masticatory muscle pain (i.e., pain greater than three months) or patients with burning mouth syndrome participate in this study. The aim of the study is to compare the pain killing effectiveness of nalbuphine, a narcotic pain killer, administered with either placebo or naloxone, a drug used to treat opiate overdose. A second goal is to determine if there are sex differences in these two drug regimens. Drugs will be administered with single-use intranasal spray devices. All participants will receive two sprays (one spray per nostril). One of the two sprays will be nalbuphine (5 mg). The other spray will be naloxone in half the participants and placebo in the other half.


Inclusion Criteria: - Clinical diagnosis of temporomandibular muscle pain OR - Clinical diagnosis of burning mouth syndrome - Pain duration: at least 3 months - Pain severity: 2 or greater on a 0 - 10 scale Exclusion Criteria: - No adverse reaction to study drugs - Not currently using narcotic analgesic drugs



Primary Contact:

Principal Investigator
Jon D Levine, MD, PhD
University of California, San Francisco

Backup Contact:


Location Contact:

San Francisco, California 94143
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.